NCT04882917: First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver) Solid Tumors 410

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with tumors harboring previously identified ATM mutations

Comments are closed.

Up ↑